bispecific t-cell engagers in the treatment of myeloma
Published 3 years ago • 437 plays • Length 3:59Download video MP4
Download video MP3
Similar videos
-
2:49
the value of bispecific t-cell engager therapies in myeloma & future considerations for these agents
-
3:27
the mechanism of bispecific t-cell engagers in b-all: genomic alterations
-
3:05
using patient-derived organoids to investigate bispecific t-cell engager immunotherapy in fl
-
19:39
t-cell engagers: targets, challenges and opportunity
-
8:57
outcomes of sct in t-all and t-lbl
-
9:25
mgus diagnosis: a step-by-step approach
-
3:56
the future of cancer treatment is here: introducing proton therapy
-
2:33
the role of bispecific antibodies in the treatment of patients with multiple myeloma
-
1:19
sequencing bispecific antibodies and car-t therapy & the evolving role of bispecifics in myeloma
-
4:36
rejuvinated cd8 t-cells derived from ipscs in the treatment of myeloma
-
4:15
bispecific antibodies in multiple myeloma: teclistamab, talquetamab, and cevostamab
-
0:41
mechanism of action of the tri-specific t-cell activating construct hpn217 in r/r multiple myeloma
-
2:58
bcma 2 1 t-cell engager cc-93269 in patients with r/r myeloma
-
1:41
lava-051: a novel bispecific t-cell engager for r/r hematological malignancies
-
4:58
novel immunotherapies transforming r/r myeloma treatment: bispecifics, car-t cells & more
-
1:53
the future of multiple myeloma treatment
-
0:57
insights into new bite developments in multiple myeloma
-
2:16
the sequencing of novel therapies in myeloma (car-t, bispecifics, antibody-drug conjugates)
-
2:41
cell avidity as a predictor of t-cell efficacy
-
4:58
overview of the toxicities associated with bispecific agents in multiple myeloma
-
1:59
myeloma: bites & cars